Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06679959
PHASE1/PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

Sponsor: Ascletis Pharma (China) Co., Limited

View on ClinicalTrials.gov

Summary

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection

Official title: A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

115

Start Date

2024-09-16

Completion Date

2026-04

Last Updated

2025-12-15

Healthy Volunteers

Yes

Interventions

DRUG

ASC30 Injection, for subcutaneous use or placebo

Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use

Locations (1)

Ascletis clinical site

San Antonio, Texas, United States